Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Ovarian Neoplasms

Free Subscription Articles published in Anticancer Drugs Retrieve available abstracts of 20 articles: HTML format

Single Articles

August 2023
1. ITO K, Nakagawa M, Shimokawa M, Hori K, et al
   Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601.
   Anticancer Drugs. 2023;34:857-865.
   PubMed     Abstract available
   
   
   February 2023
2. HUANG X, He X, Li D, Chen X, et al
   Advanced ovarian clear cell carcinoma with RAD50 mutation treated by PARP inhibitor pamiparib combined with anti-angiogenesis therapy: a case report.
   Anticancer Drugs. 2023;34:290-293.
   PubMed     Abstract available
   
   
   
3. HUANG Y, Zhang Y, Zhou Y, Chen Y, et al
   CDKN2B-AS1 is overexpressed in polycystic ovary syndrome and sponges miR-181a to promote granulosa cell proliferation.
   Anticancer Drugs. 2023;34:207-213.
   PubMed     Abstract available
   
   
   January 2023
4. LUO J, Zhang Y, Zheng T, Jing Y, et al
   Application of long non-coding RNA RBAT1 in improving diagnosis and prognosis of ovarian carcinoma.
   Anticancer Drugs. 2023;34:9-14.
   PubMed     Abstract available
   
   
   December 2022
5. HUANG C, Qin L, Chen S, Huang Q, et al
   CircSETDB1 contributes to paclitaxel resistance of ovarian cancer cells by sponging miR-508-3p and regulating ABCC1 expression.
   Anticancer Drugs. 2022 Dec 5. doi: 10.1097/CAD.0000000000001465.
   PubMed     Abstract available
   
   
   November 2022
6. LU M, Gong B, Wang Y, Li J, et al
   CircBNC2 affects epithelial ovarian cancer progression through the miR-223-3p/LARP4 axis.
   Anticancer Drugs. 2022 Nov 17. doi: 10.1097/CAD.0000000000001423.
   PubMed     Abstract available
   
   
   
7. SHENG H, Wang X
   Knockdown of circ-PIP5K1A overcomes resistance to cisplatin in ovarian cancer by miR-942-5p/NFIB axis.
   Anticancer Drugs. 2022 Nov 16. doi: 10.1097/CAD.0000000000001406.
   PubMed     Abstract available
   
   
   
8. WEI L, He W, Zhao H, Zhao P, et al
   Circ_0026123 promotes cisplatin resistance and progression of ovarian cancer by upregulating RAB1A through sequestering miR-543.
   Anticancer Drugs. 2022;33:1069-1080.
   PubMed     Abstract available
   
   
   September 2022
9. WANG X, Zhao H, Wang P, Zhang J, et al
   MiR-30a-5p/CHD1 axis enhances cisplatin sensitivity of ovarian cancer cells via inactivating the Wnt/beta-catenin pathway.
   Anticancer Drugs. 2022 Sep 30. pii: 00001813-990000000-00056.
   PubMed     Abstract available
   
   
   
10. SUN D, Shang D, Miao P, Jiang Z, et al
    MiR-4284 inhibits sensitivity to paclitaxel in human ovarian carcinoma SKOV3ip1 and HeyA8 cells by targeting DMC1.
    Anticancer Drugs. 2022;33:701-709.
    PubMed     Abstract available
    
    
    August 2022
11. SHAN Y, Zhang B, Chen L, Zhang H, et al
    Herpesvirus entry mediator regulates the transduction of Tregs via STAT5/Foxp3 signaling pathway in ovarian cancer cells.
    Anticancer Drugs. 2022 Aug 9. pii: 00001813-990000000-00021.
    PubMed     Abstract available
    
    
    
12. ZHANG X, Hong S, Yang J, Liu J, et al
    Purvalanol A induces apoptosis and reverses cisplatin resistance in ovarian cancer.
    Anticancer Drugs. 2022 Aug 9. pii: 00001813-990000000-00018.
    PubMed     Abstract available
    
    
    March 2022
13. MICHA J, Rettenmaier M, Giuliano P, Bohart R, et al
    Oncolytic viral therapy engenders a clinical response in a recurrent ovarian cancer patient.
    Anticancer Drugs. 2022 Mar 23. pii: 00001813-900000000-98204.
    PubMed     Abstract available
    
    
    
14. FANG W, Xia Y
    LncRNA HLA-F-AS1 attenuates the ovarian cancer development by targeting miR-21-3p/PEG3 axis.
    Anticancer Drugs. 2022 Mar 8. pii: 00001813-900000000-98225.
    PubMed     Abstract available
    
    
    September 2021
15. ROSE PG, Yao M, Chambers LM, Mahdi H, et al
    PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.
    Anticancer Drugs. 2021 Sep 13. pii: 00001813-900000000-98269.
    PubMed     Abstract available
    
    
    August 2021
16. PARK GB, Jeong JY, Choi S, Yoon YS, et al
    Glucose deprivation enhances resistance to paclitaxel via ELAVL2/4-mediated modification of glycolysis in ovarian cancer cells.
    Anticancer Drugs. 2021 Aug 19. pii: 00001813-900000000-98297.
    PubMed     Abstract available
    
    
    July 2021
17. SUN S, Sun W, Xiang Q, Yang C, et al
    Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report.
    Anticancer Drugs. 2021 Jul 30. pii: 00001813-900000000-98352.
    PubMed     Abstract available
    
    
    March 2021
18. WEI S, Qi L, Wang L
    Overexpression of circ_CELSR1 facilitates paclitaxel resistance of ovarian cancer by regulating miR-149-5p/SIK2 axis.
    Anticancer Drugs. 2021 Mar 16. pii: 00001813-900000000-98432.
    PubMed     Abstract available
    
    
    January 2021
19. ZHANG W, Huang X, Shi J
    EZH2-mediated lncRNA ABHD11-AS1 promoter regulates the progression of ovarian cancer by targeting miR-133a-3p.
    Anticancer Drugs. 2021 Jan 22. pii: 00001813-900000000-98466.
    PubMed     Abstract available
    
    
    June 2020
20. HU H, Zhu S, Tong Y, Huang G, et al
    Antitumor activity of triptolide in SKOV3 cells and SKOV3/DDP in vivo and in vitro.
    Anticancer Drugs. 2020;31:483-491.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.